Cargando…
Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk
BACKGROUND: Type 2 diabetes (T2DM) is a major risk factor for developing cardiovascular disease (CVD). The growing epidemic of T2DM has contributed to CVD becoming the leading cause of morbidity and mortality in the United States. OBJECTIVES: To review the pathophysiology of CVD; to demonstrate the...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437557/ https://www.ncbi.nlm.nih.gov/pubmed/17330977 http://dx.doi.org/10.18553/jmcp.2007.13.s2-a.1 |
_version_ | 1785092553505243136 |
---|---|
author | Bartels, David W. Davidson, Michael H. Gong, William C. |
author_facet | Bartels, David W. Davidson, Michael H. Gong, William C. |
author_sort | Bartels, David W. |
collection | PubMed |
description | BACKGROUND: Type 2 diabetes (T2DM) is a major risk factor for developing cardiovascular disease (CVD). The growing epidemic of T2DM has contributed to CVD becoming the leading cause of morbidity and mortality in the United States. OBJECTIVES: To review the pathophysiology of CVD; to demonstrate the interrelatedness of CVD, the metabolic syndrome, and T2DM; and to discuss treatment options that may reduce the risk of CVD in patients with T2DM. SUMMARY: Recent data from the International Diabetes Federation show that the worldwide prevalence of T2DM is much higher than previously estimated. Managing patients with T2DM continues to severely burden the U.S. health care system. Furthermore, most costs associated with managing these patients are associated with treating CVD complications. Studies have shown that several agents can decrease the risk of CVD in patients with T2DM. CONCLUSIONS: To combat the diabetes epidemic, clinicians should treat patients with T2DM and prediabetes early and aggressively to control their metabolic disturbances and reduce the risk of CVD. Diet, exercise, and several pharmacologic agents have been shown to reduce the risk of CVD. |
format | Online Article Text |
id | pubmed-10437557 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Academy of Managed Care Pharmacy |
record_format | MEDLINE/PubMed |
spelling | pubmed-104375572023-08-21 Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk Bartels, David W. Davidson, Michael H. Gong, William C. J Manag Care Pharm Supplement BACKGROUND: Type 2 diabetes (T2DM) is a major risk factor for developing cardiovascular disease (CVD). The growing epidemic of T2DM has contributed to CVD becoming the leading cause of morbidity and mortality in the United States. OBJECTIVES: To review the pathophysiology of CVD; to demonstrate the interrelatedness of CVD, the metabolic syndrome, and T2DM; and to discuss treatment options that may reduce the risk of CVD in patients with T2DM. SUMMARY: Recent data from the International Diabetes Federation show that the worldwide prevalence of T2DM is much higher than previously estimated. Managing patients with T2DM continues to severely burden the U.S. health care system. Furthermore, most costs associated with managing these patients are associated with treating CVD complications. Studies have shown that several agents can decrease the risk of CVD in patients with T2DM. CONCLUSIONS: To combat the diabetes epidemic, clinicians should treat patients with T2DM and prediabetes early and aggressively to control their metabolic disturbances and reduce the risk of CVD. Diet, exercise, and several pharmacologic agents have been shown to reduce the risk of CVD. Academy of Managed Care Pharmacy 2007-03 /pmc/articles/PMC10437557/ /pubmed/17330977 http://dx.doi.org/10.18553/jmcp.2007.13.s2-a.1 Text en Copyright © 2007, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Supplement Bartels, David W. Davidson, Michael H. Gong, William C. Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk |
title | Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk |
title_full | Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk |
title_fullStr | Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk |
title_full_unstemmed | Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk |
title_short | Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk |
title_sort | type 2 diabetes and cardiovascular disease: reducing the risk |
topic | Supplement |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437557/ https://www.ncbi.nlm.nih.gov/pubmed/17330977 http://dx.doi.org/10.18553/jmcp.2007.13.s2-a.1 |
work_keys_str_mv | AT bartelsdavidw type2diabetesandcardiovasculardiseasereducingtherisk AT davidsonmichaelh type2diabetesandcardiovasculardiseasereducingtherisk AT gongwilliamc type2diabetesandcardiovasculardiseasereducingtherisk |